| Combining epigenetic drugs with other therapies for solid tumours—past lessons and future promise D Morel, D Jeffery, S Aspeslagh, G Almouzni, S Postel-Vinay Nature Reviews Clinical Oncology 17 (2), 91-107, 2020 | 340 | 2020 |
| PARP inhibition enhances tumor cell–intrinsic immunity in ERCC1-deficient non–small cell lung cancer RM Chabanon, G Muirhead, DB Krastev, J Adam, D Morel, M Garrido, ... The Journal of clinical investigation 129 (3), 1211-1228, 2019 | 278 | 2019 |
| Applications of single-cell and bulk RNA sequencing in onco-immunology M Kuksin, D Morel, M Aglave, FX Danlos, A Marabelle, A Zinovyev, ... European Journal of Cancer 149, 193-210, 2021 | 87 | 2021 |
| Epigenetic modifiers as new immunomodulatory therapies in solid tumours S Aspeslagh, D Morel, JC Soria, S Postel-Vinay Annals of Oncology 29 (4), 812-824, 2018 | 82 | 2018 |
| Targeting chromatin defects in selected solid tumors based on oncogene addiction, synthetic lethality and epigenetic antagonism D Morel, G Almouzni, JC Soria, S Postel-Vinay Annals of Oncology 28 (2), 254-269, 2017 | 74 | 2017 |
| PBRM1 deficiency confers synthetic lethality to DNA repair inhibitors in cancer RM Chabanon, D Morel, T Eychenne, L Colmet-Daage, I Bajrami, ... Cancer research 81 (11), 2888-2902, 2021 | 72 | 2021 |
| Exploiting epigenetic vulnerabilities in solid tumors: Novel therapeutic opportunities in the treatment of SWI/SNF-defective cancers RM Chabanon, D Morel, S Postel-Vinay Seminars in Cancer Biology 61, 180-198, 2020 | 36 | 2020 |
| DNA repair deficiency sensitizes lung cancer cells to NAD+ biosynthesis blockade M Touat, T Sourisseau, N Dorvault, RM Chabanon, M Garrido, D Morel, ... The Journal of Clinical Investigation 128 (4), 1671-1687, 2018 | 27 | 2018 |
| Radiotherapy as a means to increase the efficacy of T-cell therapy in solid tumors PA Laurent, D Morel, L Meziani, S Depil, E Deutsch Oncoimmunology 12 (1), 2158013, 2023 | 12 | 2023 |
| Practice changing data and emerging concepts from recent radiation therapy randomised clinical trials S Espenel, C Chargari, P Blanchard, S Bockel, D Morel, S Rivera, A Levy, ... European Journal of Cancer 171, 242-258, 2022 | 7 | 2022 |
| Radio-induced lymphopenia in the era of anti-cancer immunotherapy F de Kermenguy, L Meziani, M Mondini, C Clémenson, D Morel, ... International Review of Cell and Molecular Biology 378, 1-30, 2023 | 6 | 2023 |
| Otorhinolaryngological toxicities of new drugs in oncology DM Hartl, D Morel, E Saavedra, C Massard, A Rinaldo, NF Saba, A Ferlito, ... Advances in therapy 34, 866-894, 2017 | 4 | 2017 |
| Sustained cancer clinical trial activity in a French hospital during the first wave of the COVID-19 pandemic A Bayle, C Baldini, P Martin-Romano, JM Michot, S Champiat, R Bahleda, ... Cancer Cell 39 (8), 1039-1041, 2021 | 2 | 2021 |
| DeepOS: pan-cancer prognosis estimation from RNA-sequencing data M Pavageau, L Rebaud, D Morel, S Christodoulidis, E Deutsch, ... medRxiv, 2021.07. 10.21260300, 2021 | 2 | 2021 |
| Targeting chromatin remodeling-associated genetic vulnerabilities in cancer: PBRM1 defects are synthetic lethal with PARP and ATR inhibitors RM Chabanon, D Morel, L Colmet-Daage, T Eychenne, N Dorvault, ... Cancer Research 80 (16_Supplement), 1058-1058, 2020 | 2 | 2020 |
| Epigenetic gene alterations in metastatic solid tumours: Results from the prospective precision medicine MOSCATO and MATCH-R trials P Martin-Romano, L Colmet-Daage, D Morel, C Baldini, L Verlingue, ... European Journal of Cancer 173, 133-145, 2022 | 1 | 2022 |
| PC-FACS X Hu, C Jiang, Q Fan, KS Shi, RB Parikh, AH Kamal, RT Anderson, ... | | 2024 |
| LymphoDose: a lymphocyte dose estimation framework—application to brain radiotherapy F de Kermenguy, N Benzazon, P Maury, R Vauclin, M M’hamdi, V Cifliku, ... Physics in Medicine & Biology 69 (10), 105009, 2024 | | 2024 |
| Translational Frontiers and Clinical Opportunities of Immunologically Fitted Radiotherapy D Morel, C Robert, N Paragios, V Grégoire, E Deutsch Clinical Cancer Research, OF1-OF16, 2024 | | 2024 |
| An international phase II trial and immune profiling of SBRT and atezolizumab in advanced pretreated colorectal cancer A Levy, D Morel, M Texier, R Sun, J Durand-Labrunie, ... Molecular Cancer 23 (1), 61, 2024 | | 2024 |
